DOCSLIB.ORG

Rare Diseases Progress and Challenges Ahead

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

THERAPEUTIC DIGEST RARE DISEASES PROGRESS AND CHALLENGES AHEAD IN COLLABORATION WITH DECEMBER 2020 Rare changes everything. Every day can be delayed, postponed, or canceled when you or a loved one has a rare disease. At the Center for Rare Diseases, we never forget that rare alters entire lives. We’re committed to changing that. To find out more, visit us at rarechangeseverything.com. Pharma VOICE.com RARE DISEASES Table of Contents Rare Diseases: Progress and Challenges Ahead ............................................................. 5 Defining Rare Diseases ..................................................................................................... 6 Small Molecules ................................................................................................................ 6 Progress ............................................................................................................................... 7 Clinical Success and Approvals ............................................................................................. 8 Strengths and Limitations ...................................................................................................... 9 Antibody Therapies ........................................................................................................ 10 Progress ............................................................................................................................. 10 Clinical Success and Approvals ........................................................................................... 11 Strengths and Limitations .................................................................................................... 12 Protein Replacement Therapies ..................................................................................... 13 Progress ............................................................................................................................. 14 Clinical Success and Approvals ........................................................................................... 14 Strengths and Limitations .................................................................................................... 15 Oligonucleotide Therapies ............................................................................................. 16 Progress ............................................................................................................................. 16 Clinical Success and Approvals ........................................................................................... 17 Strengths and Limitations .................................................................................................... 18 Gene and Cell Therapy .................................................................................................. 18 Progress ............................................................................................................................. 19 Clinical Success and Approvals ........................................................................................... 21 Strengths and Limitations .................................................................................................... 22 Table: Characteristics of Therapeutic Modalities ........................................................ 23 Pie Charts: Approvals by Therapeutic Modality .......................................................... 24 Table: glossary of Terms ............................................................................................. 24 Conclusion ................................................................................................................... 26 Notes ................................................................................................................................ 27 Resources ......................................................................................................................... 34 Editorial content provided by ThinkGen (www.think-gen.com) Written by Kristina Erfe Pines DECEMBER 2020 3 DIGITAL THERAPEUTICS Q&A with PRA’s Juliane Mills How are rare disease clinical trials different from Juliane Mills traditional clinical trials? Director, PRA Center for Rare Diseases Every patient is a precious resource in clinical research. PRA Health Sciences When conducting a clinical trial in a rare disease, there are by definition only a few eligible patients who can participate in a clinical trial. If someone drops out, there may not be anyone else to invite. The way we engage with patients needs to be reflective of the value of their participation. This means doing all we can to make it easy to volunteer such as with plain-language patients are partners in the journey. Patients should communication, reimbursement for time and travel, be empowered to do their own reading, talk to other and carefully planning visit procedures. people who have the same symptoms, and share their Rare disease trials are also different due to the ideas about treatment with their doctor. It’s never a statistical challenges when researching a low number one-way street. of patients. Just as every patient is precious, every data point is critically important. Because there are fewer patients, there are less data overall, and we may 90% of all rare disorders do not have an FDA- not have the statistical power in rare disease trials to approved treatment. How can the R&D process discriminate noise from a true signal. To reduce ‘noise’ address the smaller patient populations inherent in the data set, the methods used to collect data need with orphan or rare disease trials? to be standardized. We need to make sure every trial Registries are often set up by R&D companies, but site in a study is consistently using the same staff more and more we see advocacy groups setting them and the same methods to assess each patient. Every up and encouraged to do so by regulatory authorities. person involved, from the doctors administering the When advocacy groups set up registries on their own, assessment to the study coordinators and site staff, they can democratize ownership of all this data, which must follow the same procedures. puts ownership in the hands of patients. By building registries populated with shareable observational data, we can establish consensus in rare disease research Many families search for a diagnosis for years. and form a better singular view into these patient Historically, it’s been incredibly difficult to obtain populations. an accurate diagnosis. Some studies have estimated that up to 40% of rare disease patients As we share what we know about rare diseases, we are misdiagnosed at least once. What can be done find that some rare diseases operate in the same to change how rare diseases are diagnosed? biological pathway but may manifest with very different symptoms. Even though these patients have the When patients are misdiagnosed or bounced around same disease pathway, different types of doctors may from doctor to doctor, it can certainly upend the doctor- treat them depending on where the symptoms occur. patient relationship. Sometimes a diagnosis of a rare Advocacy groups have been bringing together doctors disease is a process of ruling out other diseases, which from all different specialties as well as academic means a lot of tests, painful procedures, and time. The researchers to build consensus on biomarkers, disease lack of answers can completely erode a patient’s faith in terminology, and treatments. n the medical system. Honesty on both sides of the patient-doctor relationship is a great way to move forward. Doctors need to be ____________________________________________________ willing to hear and listen to what patients are telling By partnering with patients in your rare disease them. Conversely, patients need to understand that research, you can develop more meaningful endpoints. doctors may not have all the answers. Doctors and Learn how in our latest white paper. 1220-TherapeuticDigest-PRA-120320.indd 1 12/10/20 11:44 AM Pharma VOICE.com RARE DISEASES Rare Diseases Progress and Challenges Ahead Rare diseases, also known as orphan disease, are a group of disorders that affects a small percentage of the population. Commonly presenting in early life, rare disease can also be seen in adulthood with a chronic phase. These diseases are frequently progressive, disabling, and life threatening. Approximately 30% of children suffering will die at 5 years of age1. Although rare diseases affect small numbers of patients by definition, they are estimated to collectively affect ~350 million patients globally2, more than double the number of patients affected by AIDS and cancer combined. While there have been substantial efforts to promote the development of therapies for rare diseases in the past few decades, supported by regulatory and economic incentives3, most of the estimated ~7,000 rare diseases still lack specific treatments. Moreover, recent analysis indicates that the number of rare diseases could be substantially higher than 7,000. The vast majority of rare diseases are characterized by Mendelian inheritance, and the recent evolution and broader application of sequencing technologies have revealed the causes of novel rare diseases and have identified new mutations responsible for previously defined disorders4. In addition, emerging applications of advanced analytics such as facial recognition have the potential to improve the screening and diagnosis of some disorders5. Nevertheless,
Recommended publications
  • Unmet Medical Device Needs for Patients with Rare Diseases

    Unmet Medical Device Needs for Patients with Rare Diseases

    Contents Page i CONTENTS Executive Summary ...................................................................................................................... ii Background ................................................................................................................................. ii Methods ....................................................................................................................................... ii Survey Respondents ................................................................................................................... iii Findings ...................................................................................................................................... iii Introduction ................................................................................................................................... 1 Unmet Device Needs in Rare Diseases ....................................................................................... 1 Purpose of This Needs Assessment ............................................................................................. 2 Methods .......................................................................................................................................... 4 Stakeholder Consultations ........................................................................................................... 4 Survey Methodology ..................................................................................................................
  • Disease Gene Mapping in Isolated Human Populations: the Example of Finland

    Disease Gene Mapping in Isolated Human Populations: the Example of Finland

    J Med Genet 1993; 30: 857-865 857 MEDICAL GENETICS AROUND THE WORLD J Med Genet: first published as 10.1136/jmg.30.10.857 on 1 October 1993. Downloaded from Disease gene mapping in isolated human populations: the example of Finland Albert de la Chapelle The recent surge of interest in isolated human published ones. Moreover, ascertainment is populations can be attributed largely to the usually more complete in Finland than in advances in molecular genetics that now ap- many other populations. Third, not surpris- pear to produce an endless array of new data. ingly, recent evidence suggests that the figures However, the organised study of inherited for cases 'elsewhere' will often turn out to be traits and disorders in isolated populations much higher. For instance, retinoschisis is started several decades ago. For example, at increasingly diagnosed in unrelated patients the beginning of the second half of this century worldwide,'3 progressive myoclonus epilepsy several enthusiastic investigators at the De- appears to be quite prevalent in the Mediter- partment of Paediatrics, University ofHelsinki ranean region,'4 and congenital chloride diar- began to document rare diseases in Finns that rhoea occurs with high frequency in Poland'5 either had not been previously described or and around the Persian Gulf.'6 In conclusion, were very rare elsewhere. The 'flagship' dis- however, most of the disorders listed in tables ease was congenital nephrosis described by 1 and 2 show remarkably high incidences in Hallman et all and established as an autosomal Finland relative to most other populations. recessive disorder by Norio.2 These were the heydays of biochemical genetics.
  • Orphan Drug Act and the Development of Products for Rare Diseases

    Orphan Drug Act and the Development of Products for Rare Diseases

    The Orphan Drug Act and the Development of Products for Rare Diseases Mathew T. Thomas, MD Office of Orphan Products Development Food and Drug Administration Telephone: 301-827-3666 Email: [email protected] The Office of Orphan Drug Development at the FDA works closely and in collaboration with the Office of Rare Disease Research Presentation Outline • Orphan Drug Act (1983) • “Orphan” drugs and diseases • Functions of the Office of Orphan Product Development (OOPD) • Financial incentives of orphan drug status • OOPD grant program • Incentive for tropical disease products • OOPD device regulation TheThe U.S.U.S. OrphanOrphan DrugDrug ActAct (ODA)(ODA) SignedSigned inin 19831983 US Congress established the public policy that the Federal Government could/would assist in the development of products for the diagnosis, prevention or treatment of rare diseases or conditions. WhatWhat isis anan OrphanOrphan Drug?Drug? • A drug (or biologic) intended to treat a rare disease or condition affecting fewer than 200,000 persons in the United States or • A drug (or biologic) which will not be profitable within 7 years following approval by the U.S. Food & Drug Administration What is an Orphan Disease? • Affects <200,000 persons in the US • Affects >200,000 in US, no expectation that therapeutic development costs will be recovered from sales in the US • 6,000 rare diseases • Affects 25 million Americans Principle functions of the FDA Office of Orphan Product Development. 1. Designate drugs as having “orphan status” 2. Award grants for clinical
  • 1St Quarter 2020

    1St Quarter 2020

    1st Quarter, 2020 PORPHYRIA AWARENESS WEEK 2020 APRIL 18-25 #ASKMEABOUTPORPHYRIA Porphyria Awareness week is an op- pated in health fairs, educational seminars, portunity for you to create awareness fundraising and various media events. As in your community! We strive to dedicate we prepare for Porphyria Awareness Week, this week to promote Porphyria, reduce the we want to encourage you to enhance and stigma associated with porphyria through raise porphyria awareness within your local education and provide support for those communities. affected. The American Porphyria Foundation will The American Porphyria Foundation is here continue to partner with other internation- to support you with ideas, brochures, ma- al porphyria advocacy organizations to in- terials, social media fi les (including Logo crease awareness around porphyria. Files, DVDs, Porphyria Fact Sheets, Press Release – and any other support that you What are your plans this year for Porphyr- may need to raise awareness about Por- ia Awareness Week? We want to know - phyria in your community, to the general Send your plans to Iany Schneider, APF public or to physicians. In recent years, many of you have partici- Offi ce Manager, via email at [email protected]. WHAT CAN YOU DO? Wear purple for Porphyria! Some have had a class or an offi ce Assist at medical conventions or health fairs wear purple for the day in support of porphyria. to educate laypersons and physicians on porphyria. Ask your hospital or doctor if there is a local meeting Educate friends and family. Send an email, a so- where you can hand out materials or tell your expe- cial media post, or send a letter about your experience rience.
  • Here Are Some of the Points I Would Like to Make As a Finnish Mother of a Intellectually Disabled Rare Disease Child and Patient Group Activist

    Here Are Some of the Points I Would Like to Make As a Finnish Mother of a Intellectually Disabled Rare Disease Child and Patient Group Activist

    Hi! Here are some of the points I would like to make as a Finnish mother of a intellectually disabled rare disease child and patient group activist. Question 1: Is the current EU definition of a rare disease satisfactory? I would like the words "or rare syndrome" to be included in the definition of rare disease which I otherwise agree with. Question 2: Do you agree that there is a pressing need to improve coding and classification in this area? Yes. For example microdeletion syndromes are very individual and the diagnosis or classification may be based on known phenotype of an individual gene in the microdeletion area. Question 4: Should the European Reference Networks privilege the transfer of knowledge? The mobility of patients? Both? How? I would prefer one national center for rare disease or syndromes with congenital heart conditions. We are willing to travel to the capital from the north in order to see doctors with adequate expertise. There are no specialists in the country for my child's condition. Nearest ones are in the UK but traveling there is too much to manage. As a requirement for centers of reference for rare disease I have to insist that clear practical instructions are set that include for an example intellectually disabled, non-verbal and severely disabled rare disease patients to get the same level of care as everyone else. Active control and measurement of discrimination in the health care "chain" also in the form of delay in receiving care must be required and results published EU wide. Although this might seem unneccesary in light of real cases that have to my attention recently it is not given that doctors would not refuse blood tests, IV-fluids or referrals to specialists if the patient is severely disabled or intellectually disabled and often this discrimination is not recorded in the system at all.
  • 2007 Budget Justification

    2007 Budget Justification

    DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH National Human Genome Research Institute FY 2007 Budget Page No. Organization chart............................................................................................................ 2 Appropriation language ................................................................................................... 3 Amounts available for obligation..................................................................................... 4 Justification narrative....................................................................................................... 5 Budget mechanism table.................................................................................................. 19 Budget authority by activity............................................................................................. 20 Summary of changes........................................................................................................ 21 Budget authority by object............................................................................................... 23 Salaries and expenses....................................................................................................... 24 Significant items in House and Senate Appropriations Committee Reports ................... 25 Authorizing legislation..................................................................................................... 29 Appropriations history ....................................................................................................
  • Supporting Rare Disease Drug Development: CDER's Rare Diseases Program

    Supporting Rare Disease Drug Development: CDER's Rare Diseases Program

    Supporting Rare Disease Drug Development: CDER’s Rare Diseases Program Larry Bauer Regulatory Scientist Rare Diseases Program CDER OND IO 2017 Roadmap for Engaging with the Center for Drug Evaluation and Research Disclosures -No Conflicts of Interest -Nothing to Report -Opinions expressed are personal and do not reflect those of the FDA www.fda.gov 2 Outline • Rare Diseases/Orphan Drugs • Orphan Drug Development • Special Challenges for Rare Pediatric Diseases • Rare Diseases Program • Rare Pediatric Disease Priority Review Vouchers www.fda.gov 3 Rare Diseases/Orphan Drugs Orphan/rare disease Affects <200,000 persons in the US Tend to be challenging drugs to develop Orphan Drug Act Few patients available for study passed in 1983 Highly diverse group of disorders ∗ 10 years before – 10 drugs ~7,000 different disorders approved for Most are serious, most have unmet Orphan diseases medical needs ∗ Since 1983, 500+ Affect ~30 million Americans drugs approved (9 in 2016) Collectively, a large public concern www.fda.gov 4 Orphan Drug Development *Clinical Investigations are usually conducted under an Investigational New Drug (IND) application *Orphan Drug Act does not define separate regulatory standards for the safety and effectiveness of drugs to treat rare diseases www.fda.gov 5 Orphan Drug Development *Requires at least one adequate and well-controlled trial (§314.126) *FDA is required to exercise its scientific judgment to determine the kind and quantity of data and information an applicant is required to provide for a particular drug
  • Rare Disease Genes—Lessons and Challenges Leena Peltonen1 and Annukka Uusitalo

    Rare Disease Genes—Lessons and Challenges Leena Peltonen1 and Annukka Uusitalo

    Downloaded from genome.cshlp.org on September 26, 2021 - Published by Cold Spring Harbor Laboratory Press Insight/Outlook Rare Disease Genes—Lessons and Challenges Leena Peltonen1 and Annukka Uusitalo Department of Human Molecular Genetics, National Public Health Institute and Institute of Biomedicine, University of Helsinki, FIN-00300 Helsinki, Finland The fiercest competition in the field the history of affected individuals, ground. The strategy of using only a few of human genetics takes place in the which suggests that there is one major DNA samples has been highly successful area of genetic diseases that are common ancestor mutation. This situation allows in the locus identification of many rare at the population level—this is primarily the adoption of unique strategies to diseases (Nikali et al. 1995; van Soest et attributable to the potential commercial search for a causative locus: similarity al. 1996, this issue). utilization of emerging data. However, searches for the disease locus using DNA The phenomenon of shared alleles in dissection of the molecular background samples from just a few affected indi- affected individuals or significant devia- of many extremely rare diseases has viduals and searches for shared alleles or tion in the allelic frequencies of poly- proven to be highly useful for the de- homozygosity of genotypes. Using this morphic markers in disease chromo- tailed characterization of cellular dys- approach, an initial genome scan with somes compared to control chromo- function and the identification of novel 400 markers can be carried out in just a somes is called linkage disequilibrium. metabolic pathways, broadening our few days as compared to the weeks or This is sometimes observed with mark- understanding of biological processes in months required for genotyping all fam- ers over amazingly wide intervals, as ex- general.
  • State of the Art for Rare Diseases – Activities in EU Member States and Other European Countries Finland Report Definition Of

    State of the Art for Rare Diseases – Activities in EU Member States and Other European Countries Finland Report Definition Of

    State of the Art for Rare Diseases – Activities in EU Member States and Other European Countries Finland Report Definition of a Rare Disease Finland has adopted the European Commission definition of a rare disease (i.e. a prevalence of no more than 5 per 10,000 people, as per Regulation (EC) No 141/2000) and the National Plan espouses this definition. -------- Status Quo of any National Plan or Strategy for Rare Diseases Finland adopted a National Plan for Rare Diseases. The plan covers the years 2014-2017. The Ministry of Social Affairs and Health had appointed a multidisciplinary Steering Group to prepare a proposal for a National Plan. Once the proposal was completed it was assessed and approved by the Ministry. Unfortunately, no laws or decrees relating to the National Plan were approved and a specific budget was not assigned. The Ministry, however, did provide the minimal funding required to form and run an Expert Group responsible for the realisation of the National Plan. The Ministry also provided a doctor who, on a part time basis, was tasked with working towards the goals of the National Plan. All five of the university hospitals in Finland realised that something needed to be done to streamline the diagnostics, treatment and research relating to rare diseases: this required funds and the university hospitals dedicated a budget to perusing this goal. Helsinki University Hospital, the biggest in Finland, dedicated budget to pay for the salary of a specialist MD, one nurse and a part time senior consultant and other personnel. The national plan addresses the issue of rare disease coding, stating that Finland will wait for the implementation of ICD11.
  • Rare Disease Day 2021 Information Pack

    Rare Disease Day 2021 Information Pack

    Rare Disease Day 2021 Information Pack What is Rare Disease Day? Rare Disease Day is the official international awareness-raising campaign for rare diseases which takes place on the last day of February each year. The main objective of the campaign is to raise awareness amongst the general public and decision-makers about rare diseases and their impact on patients' lives. Rare Disease Day was launched by EURORDIS-Rare Diseases Europe and its Council of National Alliances in 2008. Take part in Rare Disease Day 1 How to Show your support for Rare Disease Day 2 Join us on social media 3 Organise an event Become a friend 4 5 Tell your story 6 Take action locally Share your photos 7 Download communication materials 8 1 How to Show your support for Rare Disease Day Raising awareness of what it means to be rare There are over 300 million people worldwide living with a rare disease. Together across borders, and across the 6000+ rare diseases we work towards more equitable access to diagnosis, treatment, care and social opportunity. Our key message for Rare Disease Day 2021 is that: Rare is many. Rare is strong. Rare is proud. Find some inspiration below for ideas to take part in this year’s campaign. 1. Share a photo to show solidarity with people living with a rare disease in your community! Share a photo with painted hands on social media using #RareDiseaseDay and tag @rarediseaseday. 2. Download the Rare Disease Day logo and make it visible online. Hero the logo on flyers, t-shirts and even cake-the possibilities are endless! 3.
  • Page De Garde

    Page De Garde

    2012 REPORT ON THE STATE OF THE ART OF RARE DISEASE ACTIVITIES IN EUROPE OF THE EUROPEAN UNION COMMITTEE OF EXPERTS ON RARE DISEASES STATE OF THE ART OF RARE DISEASE ACTIVITIES IN FINLAND This work was financed by the EUCERD Joint Action: Working for Rare Diseases N° 2011 22 01 µ 2012 EUCERD Report on the State of the Art of the Rare Disease Activities in Finland This document has been produced by the Scientific Secretariat of the European Union Committee of Experts on Rare Diseases (EUCERD, formerly the European Commission’s Rare Diseases Task Force) through the EUCERD Joint Action: Working for Rare Diseases (N° 2011 22 01, Coordinator: Kate Bushby, University of Newcastle, United Kingdom), within the European Union’s Second Programme of Community Action in the Field of Health. More information on the European Union Committee of Experts on Rare Diseases can be found at www.eucerd.eu. Disclaimer: The findings and conclusions in this report are those of the contributors and validating authorities, who are responsible for the contents; the findings and conclusions do not necessarily represent the views of the European Commission or national health authorities in Europe. Therefore, no statement in this report should be construed as an official position of the European Commission or a national health authority. Copyright information: The “2012 Report on the State of the Art of Rare Disease Activities in Europe of the European Union Committee of Experts on Rare Diseases” is copyrighted by the European Union Committee of Experts on Rare Diseases (EUCERD). This product and its contents may be used and incorporated into other* materials on the condition that the contents are not changed in any way (including covers and front matter) and that no fee is charged by the reproducer of the product or its contents for their use.
  • Rare Diseases, When Taken Together, Are Are Together, When Taken Diseases, Rare to According at All

    Rare Diseases, When Taken Together, Are Are Together, When Taken Diseases, Rare to According at All

    2013 MEDICINES IN DEVELOPMENT REPORT Rare Diseases A Report on Orphan Drugs in the Pipeline PRESENTED BY AMERICA’s biopharmACEUTICAL RESEARCH COMPANIES More Than 450 Medicines in Development for Rare Diseases Rare diseases, when taken together, are A major area of this research targets Orphan Drugs in Development* not that rare at all. In fact, according to rare cancers, accounting for more than Application the National Institutes of Health (NIH), one-third of all rare disease medicines in Submitted 30 million Americans have one of the development. Other top research areas Phase III nearly 7,000 diseases that are officially include genetic disorders, neurologi- Phase II deemed “rare” because alone they each cal conditions, infectious diseases and Phase I affect fewer than 200,000 people in autoimmune disorders. the United States. Sometimes, only Despite some recent victories, research a few hundred patients are known to 105 into treatments for rare diseases is a have a particular rare disease. daunting quest. This ongoing innovation Simply receiving a diagnosis of a rare and the hundreds of new medicines in disease often becomes a frustrating development now offer hope that physi- 85 quest, since many doctors may have nev- cians will have new treatment options er before heard of or seen the disease. for patients confronting a rare disease. This is, however, a time of great progress and hope. Biopharmaceutical 65 Contents research is entering an exciting new era Innovative Orphan Drugs with a growing understanding of the in the Pipeline ......................................... 2 human genome. Scientific advances have given researchers new tools to Orphan Drug Approvals ...........................4 explore rare diseases, which are often Challenges in Clinical Trials ......................6 more complex than common diseases.